Abbott Laboratories Corporation

Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Abbott Gmbh & Co Kg

Zhen Wu

Chung-Ming Hsieh

Ulrich Ebert

Jijie Gu

Martin Schmidt

Reinhold Mueller

Volker Nimmrich

Enrico L Digiammarino

John E Harlan

Gerard B Fox

Ralf Loebbert

Feng Luo

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid &#x3b2; and advanced glycation-end-products.

Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid &#x3b2; and advanced glycation-end-products.

Growing community of inventors

Framingham, MA, United States of America

Zhen Wu